Skip to main content
SpringerLink
Log in

Biomarker-Docetaxel-basierte Chemotherapie

Biomarker docetaxel-based chemotherapy

  • Übersichten
  • Published:
Der Urologe Aims and scope Submit manuscript

Zusammenfassung

In der PSA-Ära werden mehr Patienten mit lokal begrenztem Prostatakarzinom diagnostiziert. Je nach Tumorstadium werden 10–40 % der Patienten nach initial kurativer Therapie im weiteren Verlauf progredient und benötigen eine weitere Therapie. Nach einer primären Androgendeprivation wird beim symptomatischen Patienten die Indikation zur systemischen Chemotherapie gestellt. Gerade da in jüngster Vergangenheit mehrere Medikamente zur Therapie des kastrationsresistenten Tumorstadiums zur Verfügung stehen sind sensitive Biomarker zur Verlaufskontrolle oder zur Vorhersage des Therapieansprechens erforderlich. Mit dieser Übersicht sollen wichtige Biomarker, potentielle Proteine und Targets in diesem Zusammenhang dargestellt werden.

Abstract

In the prostate-specific antigen (PSA) era, prostate cancer is detected at more local stages. Nevertheless, depending on e.g. the differentiation stage there is recurrent disease in 10-40% of the cases with the need of further treatment. Once hormonal therapy has been initiated the disease can progress to the castration resistant stage and the question of chemotherapy arises. At this stage PSA sensitivity decreases. Although there is a significant improvement in survival only about 50% of the patients benefit from chemotherapy. Recently several new drugs have or will soon be approved in the setting of castration-resistant prostate cancer (CRPCA). Several prognostic molecular markers have been investigated. In this review some objective important biomarkers, proteins and targets will be presented.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Boyle P, Ferlay J (2005) Cancer incidence and mortality in Europe 2004. Ann Oncol 16(3):481–488

    Article  PubMed  CAS  Google Scholar 

  2. Tannock I, deWit R, Berry W et al (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351:1502–1512

    Article  PubMed  CAS  Google Scholar 

  3. Petrylak D, Tangen C, Hussain M et al (2004) Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351:1513–1520

    Article  PubMed  CAS  Google Scholar 

  4. Bono JS de, Oudard S, Ozguroglu M et al (2010) Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 376(9747):1147–1154

    Article  PubMed  Google Scholar 

  5. Bono JS de, Logothetis CJ, Molina et al (2011) Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 364(21):1995–2005

    Article  PubMed  Google Scholar 

  6. Scher HI, Fizazi K, Saad F et al (2012) Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 367(13):1187–1197

    Article  PubMed  CAS  Google Scholar 

  7. Parker C, Heinreich D, O’Sullivan JM et al (2011) Overall survival benefit of radium-223 chloride (Alpharadin) in the treatment of patients with symptomatic bone metastases in castrationresistant prostate cancer: a phase III randomized trial (ALSYMPCA). Eur J Cancer 47(Suppl 2):3

    Article  Google Scholar 

  8. Smaletz O, Scher HI, Small EJ et al (2002) Nomogram for overall survival of patients with progressive metastatic prostate cancer after castration. J Clin Oncol 20:3972–3982

    Article  PubMed  Google Scholar 

  9. Halabi S, Small EJ, Kantoff PW et al (2003) Prognostic model predicting survival in men with hormone-refractory metastatic prostate cancer J Clin Oncol 21:1232–1237

    Google Scholar 

  10. Olbert P, Hegele A, Kraeuter P et al (2006) Clinical significance of a prostate – specific antigen flare phenomenon in patients with hormone-refractory prostate cancer receiving docetaxel. Anticancer Drugs 17(8):993–996

    Article  PubMed  CAS  Google Scholar 

  11. Nelius T, Filleur S (2009) PSA surge/flare-up in patients with castration-refractory prostate cancer during the initial phase of chemotherapy. Prostate 69:1802–1807

    Article  PubMed  CAS  Google Scholar 

  12. Scher H, Halabi S, Tannock I et al (2008) Design and end pints of clinical trials for patients with progressive prostate cancer and castrate levels of testosteron: recommendations of the Prostate Clinical Trials Working Group. J Clin Oncol 26:1148–1159

    Article  PubMed  Google Scholar 

  13. Armstrong A, Garrett-Mayer E, Yang Y et al (2007) Prostate-specific antigen and pain surrogacy analysis in metastatic hormone refractory prostate cancer. J Clin Oncol 26:3965–3970

    Article  Google Scholar 

  14. QU YY, Dai B, Kong YY et al (2013) Prognostic factors in Chinese patients with metastatic castration – resistant prostate cancer treated with docetaxel-based chemotherapy. Asian J Androl 15:110–115

    Article  PubMed  CAS  Google Scholar 

  15. Sonpavde G, Pond G, Berry W et al (2012) Serum alkaline phosphatase changes predict survival independent of PSA changes in men with castration-resistant prostate cancer and bone metastasis receiving chemotherapy. Urol Oncol 30(5):607–613

    Article  PubMed  CAS  Google Scholar 

  16. Armstrong A, Garrett-Mayer E, deWit R et al (2010) Prediction of survival following first-line chemotherapy in men with castration-resistant metastatic prostate cancer. Clin Cancer Res 16:203–211

    Article  PubMed  CAS  Google Scholar 

  17. Pond G, Armstrong A, Wood B et al (2012) Ability of C-reactive protein to complement multiple prognostic classifiers in men with metastatic castration resistant prtostate cancer receiving docetaxel-based chemotherapy. BJU Int 110:461–468

    Article  Google Scholar 

  18. Beer T, Lalani A, Lee S et al (2008) C-reactive protein as a prognostic marker form en with androgen-independent prostate cancer: results from the ASCENt trial. Cancer 112:2377–2383

    Article  PubMed  CAS  Google Scholar 

  19. Prins R, Rademacher B, Mongoue-Tchokote S et al (2010) C-reactive protein as an adverse prognostic marker form en with castration – resistant prostate cancer (CRPC): confimratory results. Urol Oncol 30:33–37

    PubMed  Google Scholar 

  20. Bono J de, Scher H, Montgomery R et al (2008) Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res 14(19):6302–6309

    Article  PubMed  Google Scholar 

  21. Yoshino T, Shiina H, Urakami S et al (2006) Bcl-2 expression as a predictive marker of hormone-refractory prostate cancer treated with taxane-based chemotherapy. Clin Cancer Res 12:6116–6124

    Article  PubMed  CAS  Google Scholar 

  22. Bree C, Savonije J, Franken N et al (2000) The effect of p53-function on the sensitivity to paclitaxel with or without hyperthermia in human colorectal carcinoma cells. Int J Oncol 16(4):739–744

    PubMed  Google Scholar 

  23. Swanson T, Krueger S, Galoforo S et al (2011) TMPRSS2/ERG fusion gene expression alters chemo- and radio-responsiveness in cell culture models of androgen independent prostate cancer. Prostate doi:10.1002/pros.21371

    Google Scholar 

  24. Dumontet C, Sikic B (1999) Mechanism of action and of resistance to antitubulin agents: microtubule dynamics, drug transport and cell death. J Clin Oncol 17:1061–1070

    PubMed  CAS  Google Scholar 

  25. Ferrandina G, Zannoni G, Martinelli E et al (2006) Class III β-tubulin overexpression is a marker of poor clinical outcome in advanced ovarian cancer patients. Clin Cancer Res 12:2774–2779

    Article  PubMed  CAS  Google Scholar 

  26. Galmarini C, Treilleux I, Cardoso F et al (2008) Class III β – tubulin isotope predictsresponse in advancedbreast cancer patients randomly treated either with single-agent doxorubicin or docetaxel. Clin Cancer Res 14:4511–4516

    Article  PubMed  CAS  Google Scholar 

  27. Seve P, Mackey J, Isaac S et al (2005) Class III β-tubulin expression in tumor cells predicts response and outcome in patients with non small cell lung cancer receiving paclitaxel. Mol Cancer Ther 4:2001–2007

    Article  PubMed  CAS  Google Scholar 

  28. Terry S, Ploussard G, Allory Y et al (2009) Increased expression of class III β-tubulin in castration resistant human prostate cancer. Br J Cancer 101:951–956

    Article  PubMed  CAS  Google Scholar 

  29. Ploussard G, Terry S, Maille P et al (2010) Class III β-tubulin expression predicts prostate tumor aggressiveness and patient response to docetaxel-based chemotherapy. Cancer Res 70:9253–9264

    Article  PubMed  CAS  Google Scholar 

  30. Efstathiou E, Titus M, Tsavachidou D et al (2012) Effects of Abiraterone Acetat on Androgen signaling in castrate-resistant prostate cancer in bone. J Clin Oncol 30:637–643

    Article  PubMed  CAS  Google Scholar 

Download references

Einhaltung ethischer Richtlinien

Interessenkonflikt. D. Pfister, A. Heidenreich und D. Porres geben an, dass kein Interessenkonflikt besteht. Dieser Beitrag beinhaltet keine Studien an Menschen oder Tieren

Author information

Authors and Affiliations

  1. Klinik für Urologie, Universitätsklinikum Aachen, Pauwelsstraße 30, 52074, Aachen, Deutschland

    D. Pfister, A. Heidenreich & D. Porres

Authors
  1. D. Pfister
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A. Heidenreich
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. D. Porres
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to D. Pfister.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Pfister, D., Heidenreich, A. & Porres, D. Biomarker-Docetaxel-basierte Chemotherapie. Urologe 52, 1261–1264 (2013). https://doi.org/10.1007/s00120-013-3318-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00120-013-3318-y

Schlüsselwörter

Keywords

Search

Navigation